Department of Pathology, Yeungnam University College of Medicine, 170, Hyeonchung-ro, Nam-gu, Daegu 705-717, Republic of Korea.
Virchows Arch. 2013 Jun;462(6):603-7. doi: 10.1007/s00428-013-1425-1. Epub 2013 May 24.
Human epidermal growth factor receptor 2 (HER2/neu) gene amplification and HER2 protein overexpression have been associated with clinicopathological parameters and clinical outcome in many carcinomas. The aim of this study was to evaluate the frequency and prognostic impact of HER2 protein overexpression and gene amplification in small intestinal carcinoma (SIC). We performed immunohistochemistry (IHC) for HER2 protein and silver in situ hybridization for the HER2 gene in a total of 194 SICs. A total of 184 cases (94.8 %) were IHC 0 and 6 cases (3.1 %) were IHC 1+ with no gene amplification. HER2 protein overexpression (IHC 3+) with concordant gene amplification was detected in four cases (2.1 %), using the American Society of Clinical Oncology-College of American Pathologists guidelines for breast cancer. HER2 gene amplification was observed in an equivocal (IHC 2+) metastatic tumor in lymph node. No significant correlation was observed between HER2 status and clinicopathological parameters. Although HER2 protein overexpression and amplification were rare and did not correlate with clinicopathological parameters, further studies will be necessary to answer the question as to whether adjuvant therapy targeting the HER2 receptor might improve outcome in patients with a SIC with HER2 gene amplification and protein overexpression.
人类表皮生长因子受体 2（HER2/neu）基因扩增和 HER2 蛋白过表达与许多癌症的临床病理参数和临床结果相关。本研究旨在评估小肠癌（SIC）中 HER2 蛋白过表达和基因扩增的频率及其对预后的影响。我们对总共 194 例 SIC 进行了 HER2 蛋白免疫组化（IHC）和 HER2 基因的银原位杂交检测。共有 184 例（94.8%）为 IHC0，6 例（3.1%）为 IHC1+，且无基因扩增。根据美国临床肿瘤学会-美国病理学家协会乳腺癌指南，使用该方法检测到 4 例（2.1%）具有一致性基因扩增的 HER2 蛋白过表达（IHC3+）。在淋巴结的疑似（IHC2+）转移性肿瘤中观察到 HER2 基因扩增。HER2 状态与临床病理参数之间未观察到显著相关性。尽管 HER2 蛋白过表达和扩增罕见，且与临床病理参数无关，但需要进一步研究以回答针对具有 HER2 基因扩增和蛋白过表达的 SIC 患者的 HER2 受体的辅助治疗是否可能改善预后的问题。
